Press Releases

Year

Jun 22, 2022

Applied Therapeutics, Inc. Announces Pricing of $30 Million Public Offering of Common Stock and Warrants

NEW YORK, June 22, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced the pricing

Jun 22, 2022

Applied Therapeutics, Inc. Announces Public Offering of Common Stock and Warrants

Jun 03, 2022

Applied Therapeutics Receives Orphan Medicinal Product Designation from the EMA for AT-007 for Treatment of Galactosemia

NEW YORK, June 03, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced designation of AT-007

May 19, 2022

Applied Therapeutics to Present at the UBS Global Healthcare Conference

NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will participate in

May 12, 2022

Applied Therapeutics Reports First Quarter 2022 Financial Results

Continued progress in three Phase 3 trials in areas of high unmet medical need, with multiple clinical milestones expected in 2022 NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug

May 05, 2022

Applied Therapeutics to Present Data on AT-007 Treatment in SORD Deficiency at the 2022 Annual Meeting of the Peripheral Nerve Society

Sorbitol correlates with disease severity in patients with SORD Deficiency AT-007 treatment substantially reduced sorbitol levels in a pilot study in SORD Deficiency Sorbitol elevation results in mitochondrial dysfunction, neuronal loss, and climbing defects in a drosophila model of SORD

Apr 04, 2022

Applied Therapeutics to Present at the 43rd Annual Meeting of the Society for Inherited Metabolic Disorders

NEW YORK, April 04, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced poster presentations at

Mar 16, 2022

Applied Therapeutics to Present at the 2022 Annual Clinical Genetics Meeting of the American College of Molecular Genetics and Genomics

NEW YORK, March 16, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced their abstract #OP005 was

Mar 10, 2022

Applied Therapeutics Reports Fourth Quarter and Year-end 2021 Financial Results

Progress in Three Phase 3 Trials in Areas of High Unmet Clinical Need, with Multiple Clinical and Regulatory Milestones Expected in 2022 NEW YORK, March 10, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel

Mar 01, 2022

Applied Therapeutics to Present at the Cowen and Barclays Investor Conferences

NEW YORK, March 01, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will participate

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 13

Desktop - About Us

Desktop - Pipeline

Desktop - Patients & Caregivers

Desktop - Investor Menu

Mobile Header Links

Footer Disclaimer Links

Social Links

Social Links

Footer Disclaimer Links